Lombard Odier Asset Management Switzerland SA Grows Stock Position in Thermo Fisher Scientific Inc. $TMO

Lombard Odier Asset Management Switzerland SA lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,490 shares of the medical research company’s stock after purchasing an additional 1,128 shares during the period. Lombard Odier Asset Management Switzerland SA’s holdings in Thermo Fisher Scientific were worth $5,875,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock worth $13,700,154,000 after buying an additional 309,207 shares in the last quarter. Norges Bank purchased a new stake in Thermo Fisher Scientific during the second quarter valued at about $2,264,615,000. Franklin Resources Inc. increased its position in Thermo Fisher Scientific by 11.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after purchasing an additional 498,238 shares in the last quarter. Amundi raised its stake in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock valued at $1,426,316,000 after acquiring an additional 168,197 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in Thermo Fisher Scientific by 2.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock valued at $1,216,612,000 after purchasing an additional 74,971 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.9%

NYSE TMO opened at $567.87 on Tuesday. The stock has a market cap of $213.35 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 4.19 and a beta of 0.90. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm’s 50 day moving average price is $561.82 and its two-hundred day moving average price is $487.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. TD Cowen upped their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a report on Sunday. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $612.95.

Insider Buying and Selling

In other news, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michel Lagarde sold 22,046 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the transaction, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. The trade was a 20.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.